NCT04044859 - ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

August 20, 2019

Primary Completion Date

December 23, 2025

Study Completion Date

April 30, 2037

Conditions

Endometrial CancerEsophageal CancerEsophagogastric Junction (EGJ)Gastric (Stomach) CancerHead and Neck CancerMelanomaOvarian CancerNon-small Cell Lung (NSCLC)Urothelial Cancer

Interventions

GENETIC

Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks

Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1 alone or in combination with either nivolumab 480 mg IV every four weeks or pembrolizumab 400mg IV every 6 weeks

Trial Locations (17)

10065

Memorial Sloan Kettering Cancer Center, New York

27710

Duke University Medical Center, Duke Cancer Institute, Durham

28040

Hospital Universitario Fundacion Jimenez Diaz, Madrid

28041

Hospital Universitario 12 De Octubre, Madrid

28050

Hospital Universitario HM Sanchinarro CIOCC, Madrid

31008

Clinica Universitaria de Navarra, Pío

32806

Name of Institution: Orlando Health Cancer Institute, Orlando

37203

Sarah Cannon Research Institute, Nashville

41013

Hospital Universitario Virgen del Rocio, Seville

46010

Hospital Clinico de Valencia, Ibanez

53226

Froedtert Hospital and the Medical College of Wisconsin, Milwaukee

63110

Washington University - School of Medicine, St Louis

73104

OU Health Stephenson Cancer Center, Oklahoma City

77030

M.D. Anderson Cancer Center, Houston

02114

Massachusetts General Hospital, Boston

M5G 2M9

Princess Margaret Cancer Centre, Toronto

08035

Hospital Universitario Vall d'Hebron, Barcelona